Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pieter Sonneveld

Showing results (1-10 of 427) with videos related to

Pageof 43
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2017
Management of multiple myeloma in the relapsed/refractory patientPieter Sonneveld
Blood|April 11, 2009
Thalidomide/dexamethasone in myeloma: a double-edged swordPieter Sonneveld
Hemasphere|April 21, 2020
EHA Scientific Working Groups: Connecting Science and Spreading Knowledge in HematologyPieter Sonneveld
Blood|March 13, 2010
More force or more smart?Pieter Sonneveld
JAMA Oncology|July 17, 2015
Multiple Myeloma--Better Drugs Ask for More Stringent EvaluationsPieter Sonneveld
Acta Haematologica|September 17, 2005
European myeloma network: the value of collaborative researchPieter Sonneveld
Blood Advances|January 4, 2018
Should minimal residual disease negativity <i>not</i> be the end point of myeloma therapy?Pieter Sonneveld
The New England Journal of Medicine|April 17, 2024
Four-Drug Therapy for Multiple Myeloma. ReplyPieter Sonneveld
Expert Review of Hematology|June 14, 2015
Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myelomaAntonio Palumbo, Pieter Sonneveld
Haematologica|April 2, 2016
Treatment of relapsed and refractory multiple myelomaPieter Sonneveld, Annemiek Broijl
Pageof 43

Showing results (1-10 of 427) with videos related to

Sort By:
Pageof 43
Hematology. American Society of Hematology. Education Program|December 10, 2017
Management of multiple myeloma in the relapsed/refractory patientPieter Sonneveld
Blood|April 11, 2009
Thalidomide/dexamethasone in myeloma: a double-edged swordPieter Sonneveld
Hemasphere|April 21, 2020
EHA Scientific Working Groups: Connecting Science and Spreading Knowledge in HematologyPieter Sonneveld
Blood|March 13, 2010
More force or more smart?Pieter Sonneveld
JAMA Oncology|July 17, 2015
Multiple Myeloma--Better Drugs Ask for More Stringent EvaluationsPieter Sonneveld
Acta Haematologica|September 17, 2005
European myeloma network: the value of collaborative researchPieter Sonneveld
Blood Advances|January 4, 2018
Should minimal residual disease negativity <i>not</i> be the end point of myeloma therapy?Pieter Sonneveld
The New England Journal of Medicine|April 17, 2024
Four-Drug Therapy for Multiple Myeloma. ReplyPieter Sonneveld
Expert Review of Hematology|June 14, 2015
Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myelomaAntonio Palumbo, Pieter Sonneveld
Haematologica|April 2, 2016
Treatment of relapsed and refractory multiple myelomaPieter Sonneveld, Annemiek Broijl
Pageof 43